After the market closed Wednesday, Amgen Inc. - faced with label changes to include warnings and lowered reimbursement for two of its major products - made public its plan to reduce staff by 12 percent to 14 percent, or as many as 2,600 jobs, gaining a pre-tax savings of $1 billion to $1.3 billion in 2008. (BioWorld Today) Read More
